ITOS iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.
$18.61 +1.66 (9.79%)
As of 05/20/2022 15:59:58 EST IEX book CBOE book
Security Information
Category1:
US EquityCategory2:
Common stocksCategory3:
Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: USA
IPO date: 07/24/2020
Outstanding shares: 35,540,704
Average volume: 554,153
Market cap: $602,414,933
Current dividend yield: 0.00%
All SEC filings:
SEC Edgar Online
Quarterly filings:
10-Q
Annual filings:
10-K
Sedol: BMWXFT4
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%